Research programme: lipid-emulsion therapeutics - ResQ Pharma

Drug Profile

Research programme: lipid-emulsion therapeutics - ResQ Pharma

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator ResQ Pharma
  • Class Lipids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Poisoning

Most Recent Events

  • 24 May 2016 ResQ Pharma has patent protection for LipidRescue™ therapy in USA
  • 20 May 2016 Preclinical trials in Poisoning in Ireland (Infusion)
  • 20 May 2016 ResQ Pharma files an IND application with the US FDA for Poisoning (Infusion) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top